文献速递糖尿病肥胖与代谢综合征

脂肪组织胰岛素抵抗预测2型糖尿病合并NAFLD患者肝纤维化严重程度

Adipose Tissue Insulin Resistance Predicts the Severity of Liver Fibrosis in Patients With Type 2 Diabetes and NAFLD.
PubMed 文献 · J Clin Endocrinol Metab · 2023-01-01

在483例2型糖尿病合并NAFLD患者中,用弹性成像筛查发现11%存在显著肝纤维化(F≥2,肝硬度≥8.0 kPa)。

要点

  • 483例T2D合并NAFLD患者中11%有显著肝纤维化(肝硬度≥8.0 kPa)。
  • 仅校正BMI、AST和脂肪变后,adipo-IR仍与纤维化相关(OR 1.51,P=0.03)。
  • 校正后HOMA-IR、BMI和脂肪变均与纤维化无显著独立关联。

核心结论

  • 脂肪组织胰岛素抵抗(adipo-IR)与T2D合并NAFLD患者的晚期肝纤维化独立相关,其作用超出BMI和脂肪变本身。

研究设计与样本

  • 在大学门诊通过弹性成像筛查T2D患者的肝脂肪变和纤维化,共纳入483例,检测常规代谢指标、细胞角蛋白-18及HOMA-IR/adipo-IR。

主要发现

  • 11%的患者存在临床显著肝纤维化(F≥2,肝硬度≥8.0 kPa),这些患者代谢综合征特征更多、脂联素更低,AST、ALT、肝脂肪和细胞角蛋白-18更高(P<0.05-0.01)。
  • 加入代谢指标和细胞角蛋白-18的模型2中,仅BMI、AST和肝脂肪保持显著。

临床怎么用

  • 作者认为,靶向脂肪组织应成为NAFLD治疗的优先方向。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Although type 2 diabetes (T2D) is a risk factor for liver fibrosis in nonalcoholic fatty liver disease (NAFLD), the specific contribution of insulin resistance (IR) relative to other factors is unknown. OBJECTIVE: Assess the impact on liver fibrosis in NAFLD of adipose tissue (adipose tissue insulin resistance index [adipo-IR]) and liver (Homeostatic Model Assessment of Insulin Resistance [HOMA-IR]) IR in people with T2D and NAFLD. DESIGN: Participants were screened by elastography in the outpatient clinics for hepatic steatosis and fibrosis, including routine metabolites, cytokeratin-18 (a marker of hepatocyte apoptosis/steatohepatitis), and HOMA-IR/adipo-IR. SETTING: University ambulatory care practice. PARTICIPANTS: A total of 483 participants with T2D. INTERVENTION: Screening for steatosis and fibrosis with elastography. MAIN OUTCOME MEASURES: Liver steatosis (controlled attenuation parameter), fibrosis (liver stiffness measurement), and measurements of IR (adipo-IR, HOMA-IR) and fibrosis (cytokeratin-18). RESULTS: Clinically significant liver fibrosis (stage F ≥ 2 = liver stiffness measurement ≥8.0 kPa) was found in 11%, having more features of the metabolic syndrome, lower adiponectin, and higher aspartate aminotransferase (AST), alanine aminotransferase, liver fat, and cytokeratin-18 (P < 0.05-0.01). In multivariable analysis including just clinical variables (model 1), obesity (body mass index [BMI]) had the strongest association with fibrosis (odds ratio, 2.56; CI, 1.87-3.50; P < 0.01). When metabolic measurements and cytokeratin-18 were included (model 2), only BMI, AST, and liver fat remained significant. When fibrosis stage was adjusted for BMI, AST, and steatosis (model 3), only Adipo-IR remained strongly associated with fibrosis (OR, 1.51; CI, 1.05-2.16; P = 0.03), but not BMI, hepatic IR, or steatosis. CONCLUSIONS: These findings pinpoint to the central role of dysfunctional, insulin-resistant adipose tissue to advanced fibrosis in T2D, beyond simply BMI or steatosis. The clinical implication is that targeting adipose tissue should be the priority of treatment in NAFLD.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Kalavalapalli S, Leiva EG, Lomonaco R, et al. Adipose Tissue Insulin Resistance Predicts the Severity of Liver Fibrosis in Patients With Type 2 Diabetes and NAFLD. J Clin Endocrinol Metab. 2023. PMID: 36378995. doi:10.1210/clinem/dgac660

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。